BR9604881A - Composição, método de obtenção de um efeito quimioprotetor coloretal com toxicidade gastrointestinal reduzida e métodode tratamento de doença neoplástica com toxicidade gastrointestinal reduzida - Google Patents
Composição, método de obtenção de um efeito quimioprotetor coloretal com toxicidade gastrointestinal reduzida e métodode tratamento de doença neoplástica com toxicidade gastrointestinal reduzidaInfo
- Publication number
- BR9604881A BR9604881A BR9604881-6A BR9604881A BR9604881A BR 9604881 A BR9604881 A BR 9604881A BR 9604881 A BR9604881 A BR 9604881A BR 9604881 A BR9604881 A BR 9604881A
- Authority
- BR
- Brazil
- Prior art keywords
- gastrointestinal toxicity
- composition
- reduced gastrointestinal
- obtaining
- neoplastic disease
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Nutrition Science (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
"COMPOSIçãO, MéTODO DE OBTENçãO DE UM EFEITO QUIMIOPROTETOR COLORETAL COM TOXICIDADE GASTROINTESTINAL REDUZIDA E MéTODO DE TRATAMENTO DE DOENçA NEOPLáSTICA COM TOXICIDADE GASTROINTESTINAL REDUZIDA". A presente invenção se refere a composições e métodos utilizáveis na prevenção de câncer coloretal e outros canceres epiteliais gastrointestinais. A composição compreende uma R-NSAID enantiomericamente estável ou sal farmaceuticamente estável da mesma em uma quantidade eficaz para proporcionar um efeito quimioprotetor, substancialmente isenta do S-enantiómero da referida R-NSAID. O método compreender a administração da composição a um mamífero.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/402,797 US5955504A (en) | 1995-03-13 | 1995-03-13 | Colorectal chemoprotective composition and method of preventing colorectal cancer |
PCT/US1996/003495 WO1996028148A2 (en) | 1995-03-13 | 1996-03-13 | Use of a r-nsaid in a protective composition for the treatment of colorectal cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
BR9604881A true BR9604881A (pt) | 1999-11-30 |
Family
ID=23593347
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR9604881-6A BR9604881A (pt) | 1995-03-13 | 1996-03-13 | Composição, método de obtenção de um efeito quimioprotetor coloretal com toxicidade gastrointestinal reduzida e métodode tratamento de doença neoplástica com toxicidade gastrointestinal reduzida |
BR9607212-1A BR9607212A (pt) | 1995-03-13 | 1996-03-13 | Uso de uma nsaid-r em uma composição de proteção para o tratamento de cancer de colo retal |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR9607212-1A BR9607212A (pt) | 1995-03-13 | 1996-03-13 | Uso de uma nsaid-r em uma composição de proteção para o tratamento de cancer de colo retal |
Country Status (13)
Country | Link |
---|---|
US (1) | US5955504A (pt) |
EP (1) | EP0814796B1 (pt) |
JP (1) | JPH11502199A (pt) |
CN (1) | CN1183717A (pt) |
AT (1) | ATE296097T1 (pt) |
AU (1) | AU713569B2 (pt) |
BR (2) | BR9604881A (pt) |
CA (1) | CA2215329C (pt) |
DE (1) | DE69634776T2 (pt) |
DK (1) | DK0814796T3 (pt) |
ES (1) | ES2240992T3 (pt) |
PT (1) | PT814796E (pt) |
WO (1) | WO1996028148A2 (pt) |
Families Citing this family (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5981592A (en) * | 1995-03-13 | 1999-11-09 | Loma Linda University Medical Center | Method and composition for treating cystic fibrosis |
US6160018A (en) * | 1995-03-13 | 2000-12-12 | Loma Linda University Medical Center | Prophylactic composition and method for alzheimer's Disease |
US5955504A (en) * | 1995-03-13 | 1999-09-21 | Loma Linda University Medical Center | Colorectal chemoprotective composition and method of preventing colorectal cancer |
WO1997048391A2 (en) * | 1996-06-21 | 1997-12-24 | Advanced Research And Technology Institute | Methods and compositions comprising r-ibuprofen |
AU6682298A (en) * | 1997-03-10 | 1998-09-29 | Loma Linda University Medical Center | Use of r-nsaid's for the prevention of alzheimer's disease |
WO2000002555A1 (en) | 1998-07-09 | 2000-01-20 | Nardella Francis A | Methods and compositions for the treatment of chronic lymphocytic leukemia |
US6545034B1 (en) | 1999-07-23 | 2003-04-08 | The Regents Of The University Of California | Use of etodolac for the treatment of chronic lymphocytic leukemia |
US7151100B1 (en) | 1999-07-23 | 2006-12-19 | The Regents Of The University Of California | Indole compounds useful for the treatment of cancer |
US7129262B2 (en) * | 1999-07-23 | 2006-10-31 | The Regents Of The University Of California | Indole compounds useful for the treatment of cancer |
US7361680B2 (en) * | 1999-07-23 | 2008-04-22 | The Regents Of The University Of California | Indole compounds useful for the treatment of cancer |
US7105560B1 (en) * | 1999-07-23 | 2006-09-12 | The Regents Of The University Of California | Use of etodolac in the treatment of multiple myeloma |
US6432979B1 (en) | 1999-08-12 | 2002-08-13 | American Cyanamid Company | Method of treating or inhibiting colonic polyps and colorectal cancer |
CA2307278A1 (en) * | 2000-04-28 | 2001-10-28 | University Of British Columbia | Use of n-heterocyclic substituted salicylic acids for inhibition of cellular uptake of cystine |
US20040152672A1 (en) * | 2000-08-09 | 2004-08-05 | Carson Dennis A. | Indole compounds useful for the treatment of cancer |
JP2005508838A (ja) | 2001-03-23 | 2005-04-07 | アフトン コーポレーション | 膵癌の組合せ治療 |
US20090191232A1 (en) * | 2001-05-04 | 2009-07-30 | Gevas Philip C | Combination therapy for the treatment of tumors |
US20030232794A1 (en) * | 2001-06-26 | 2003-12-18 | Cottam Howard B. | Use of STAT-6 inhibitors as therapeutic agents |
US7601846B2 (en) * | 2001-06-26 | 2009-10-13 | The Regents Of The University Of California | Compounds having activity as inhibitors of apoptosis |
US20030027867A1 (en) * | 2001-06-29 | 2003-02-06 | Myriad Genetics, Incorporated | Use of R-NSAID compounds for anti-HIV treatment |
AU2002326356A1 (en) * | 2001-07-09 | 2003-01-29 | Aphton Corporation | Treatment and prevention of cancerous and pre-cancerous conditions of the liver, lung and esophagus |
US20030143165A1 (en) * | 2002-01-25 | 2003-07-31 | Allan Evans | NSAID-containing topical formulations that demonstrate chemopreventive activity |
WO2004017967A1 (en) * | 2002-08-22 | 2004-03-04 | Cornell Research Foundation, Inc. | Multifunctional cox-2 inhibitors |
WO2004026116A2 (en) * | 2002-09-19 | 2004-04-01 | The Regents Of The University Of California | Use of etodoclac to treat hyperplasia |
US7166641B2 (en) * | 2002-10-02 | 2007-01-23 | Yung Shin Pharmaceutical Industrial Co., Ltd. | Pharmaceutically acceptable salts containing local anesthetic and anti-inflammatory activities and methods for preparing the same |
WO2005033112A2 (en) * | 2003-10-02 | 2005-04-14 | Cephalon, Inc. | Substituted indole derivatives |
WO2005095459A2 (en) * | 2004-03-29 | 2005-10-13 | Receptor Biologix, Inc. | Monoclonal antibodies to gastrin hormone |
EP2567974A3 (en) | 2004-09-22 | 2013-05-22 | Cancer Advances, Inc., | Monoclonal antibodies to progastrin |
EP1814544A4 (en) * | 2004-11-05 | 2009-12-02 | Cephalon Inc | CANCER TREATMENTS |
US8436190B2 (en) | 2005-01-14 | 2013-05-07 | Cephalon, Inc. | Bendamustine pharmaceutical compositions |
EP1688413A1 (en) * | 2005-02-03 | 2006-08-09 | Hikma Pharmaceuticals Co. Ltd. | Benzoxazole derivatives for the prophylaxis and treatment of inflammatory bowel diseases |
WO2006102439A2 (en) * | 2005-03-23 | 2006-09-28 | Florida Atlantic University | Treatment or prevention of cancer and precancerous disorders |
US8357720B2 (en) * | 2005-03-23 | 2013-01-22 | Florida Atlantic University | Treatment or prevention of cancer and precancerous disorders |
AR072777A1 (es) | 2008-03-26 | 2010-09-22 | Cephalon Inc | Formas solidas de clorhidrato de bendamustina |
CA2735899A1 (en) * | 2008-09-25 | 2010-04-01 | Cephalon, Inc. | Liquid formulations of bendamustine |
MX2011007557A (es) * | 2009-01-15 | 2011-08-12 | Cephalon Inc | Formas nuevas de bendamustina como base libre. |
US9125899B1 (en) * | 2010-06-17 | 2015-09-08 | Stc.Unm | Modulators of GTPases and their use |
EP2468270A1 (en) | 2010-12-21 | 2012-06-27 | GALENpharma GmbH | (R)-2-(3-fluoro-4-phenylphenyl)propionic acid for use in the treatment of skin diseases |
WO2013168167A1 (en) | 2012-05-10 | 2013-11-14 | Painreform Ltd. | Depot formulations of a hydrophobic active ingredient and methods for preparation thereof |
CA3066756A1 (en) | 2017-06-15 | 2018-12-20 | Cancer Advances Inc. | Compositions and methods for inducing humoral and cellular immunities against tumors and cancer |
CN115181105B (zh) * | 2022-08-26 | 2024-05-28 | 长春亿诺科医药科技有限责任公司 | R型酮咯酸的制备方法及其应用 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1091403A (en) * | 1964-01-24 | 1967-11-15 | Boots Pure Drug Co Ltd | Therapeutically active phenylalkane derivatives |
DE3824353A1 (de) * | 1988-07-19 | 1990-01-25 | Paz Arzneimittelentwicklung | Verfahren zur trennung von gemischen enantiomerer arylpropionsaeuren |
DE4028906A1 (de) * | 1990-09-12 | 1992-03-19 | Paz Arzneimittelentwicklung | Arzneimittel sowie deren herstellung und deren verwendung bei der bekaempfung von schmerzen und/oder entzuendungen und/oder fieber an tieren und menschen |
US5192753A (en) * | 1991-04-23 | 1993-03-09 | Mcgeer Patrick L | Anti-rheumatoid arthritic drugs in the treatment of dementia |
DE4140185C2 (de) * | 1991-12-05 | 1996-02-01 | Alfatec Pharma Gmbh | Ein 2-Arylpropionsäurederivat in Nanosolform enthaltendes Arzneimittel und seine Herstellung |
FR2687915B1 (fr) * | 1992-02-28 | 1995-05-05 | Rhone Poulenc Rorer Sa | Composition pharmaceutique utilisable comme analgesique contenant l'acide (benzoyl-3 phenyl)-2 propionique-(r). |
US5331000A (en) * | 1992-03-09 | 1994-07-19 | Sepracor Inc. | Antipyretic and analgesic methods and compositions containing optically pure R(-) ketoprofen |
US5382591A (en) * | 1992-12-17 | 1995-01-17 | Sepracor Inc. | Antipyretic and analgesic methods using optically pure R-ketorolac |
US6160018A (en) * | 1995-03-13 | 2000-12-12 | Loma Linda University Medical Center | Prophylactic composition and method for alzheimer's Disease |
US5955504A (en) * | 1995-03-13 | 1999-09-21 | Loma Linda University Medical Center | Colorectal chemoprotective composition and method of preventing colorectal cancer |
WO1997048391A2 (en) * | 1996-06-21 | 1997-12-24 | Advanced Research And Technology Institute | Methods and compositions comprising r-ibuprofen |
US7105560B1 (en) * | 1999-07-23 | 2006-09-12 | The Regents Of The University Of California | Use of etodolac in the treatment of multiple myeloma |
-
1995
- 1995-03-13 US US08/402,797 patent/US5955504A/en not_active Expired - Lifetime
-
1996
- 1996-03-13 WO PCT/US1996/003495 patent/WO1996028148A2/en active IP Right Grant
- 1996-03-13 DE DE69634776T patent/DE69634776T2/de not_active Expired - Lifetime
- 1996-03-13 JP JP8527818A patent/JPH11502199A/ja active Pending
- 1996-03-13 AU AU54227/96A patent/AU713569B2/en not_active Ceased
- 1996-03-13 ES ES96911306T patent/ES2240992T3/es not_active Expired - Lifetime
- 1996-03-13 DK DK96911306T patent/DK0814796T3/da active
- 1996-03-13 BR BR9604881-6A patent/BR9604881A/pt unknown
- 1996-03-13 PT PT96911306T patent/PT814796E/pt unknown
- 1996-03-13 CA CA002215329A patent/CA2215329C/en not_active Expired - Fee Related
- 1996-03-13 BR BR9607212-1A patent/BR9607212A/pt not_active IP Right Cessation
- 1996-03-13 AT AT96911306T patent/ATE296097T1/de active
- 1996-03-13 EP EP96911306A patent/EP0814796B1/en not_active Expired - Lifetime
- 1996-03-13 CN CN96192538A patent/CN1183717A/zh active Pending
Also Published As
Publication number | Publication date |
---|---|
DE69634776D1 (de) | 2005-06-30 |
WO1996028148A2 (en) | 1996-09-19 |
ES2240992T3 (es) | 2005-10-16 |
EP0814796A2 (en) | 1998-01-07 |
DE69634776T2 (de) | 2006-05-11 |
EP0814796B1 (en) | 2005-05-25 |
CN1183717A (zh) | 1998-06-03 |
AU713569B2 (en) | 1999-12-02 |
AU5422796A (en) | 1996-10-02 |
PT814796E (pt) | 2005-08-31 |
BR9607212A (pt) | 1999-11-30 |
ATE296097T1 (de) | 2005-06-15 |
CA2215329C (en) | 2007-09-04 |
US5955504A (en) | 1999-09-21 |
JPH11502199A (ja) | 1999-02-23 |
DK0814796T3 (da) | 2005-09-19 |
CA2215329A1 (en) | 1996-09-19 |
WO1996028148A3 (en) | 1996-11-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR9604881A (pt) | Composição, método de obtenção de um efeito quimioprotetor coloretal com toxicidade gastrointestinal reduzida e métodode tratamento de doença neoplástica com toxicidade gastrointestinal reduzida | |
FI973163A (fi) | Pidätyskyvyttömyyden hoitaminen käyttämällä (S)-oksibutyniiniä ja (S)-desetyylioksibutyniiniä | |
TR199801180T2 (xx) | Aneljestik etkiye sahip yeni bile�ikler. | |
MX9306239A (es) | Composicion farmaceutica que forma un gel de lecitina in vivo para la liberacion mantenida de un compuesto biologicamente activo y procedimiento para la preparacion de la misma. | |
DE60026538D1 (de) | Pharmazeutische zubereitungen die clavulansäure oder derivate enthalten zur behandlund von neurologischen störungen | |
ATE340581T1 (de) | Verfahren zur behandlung von prostaterkrankungen unter verwendung von vitamin-d-formulierungen mit verzögerter und/oder verlängerter wirkstofffreigabe | |
DK1346041T3 (da) | Terapeutiske midler og fremgangsmåder til anvendelse deraf til behandling af en amyloidogen sygdom | |
IS4972A (is) | Notkun klóbindiefnisins klíókínól við að framleiða lyfjablöndu til að meðhöndla Alzheimers-sjúkdóm | |
AU2002231889A1 (en) | Halogenated composition, method for preparing same and uses thereof | |
EE200200565A (et) | Vaskulaarse kahjustava toimega kombinatsioonravi | |
CA2339384A1 (en) | Improved method for targeted topical treatment of disease | |
PT1173201E (pt) | Metodo para o tratamento de fibrose utilizando um antagonista da subunidade alfa 4 de integrina | |
IL136733A0 (en) | Pharmaceutical composition containing sibutramine and orlistat | |
EA199800717A1 (ru) | Способ лечения заболеваний млекопитающих и цвиттерионная композиция | |
FI934680A (fi) | Arylmorfolin, framstaellning och anvaending | |
PT1237562E (pt) | Processo de preparacao de extractos de micania contendo micanolida e di-hidromicanolida e utilizacao no tratamento das doencas proliferativas | |
MY104521A (en) | Treatment of depression. | |
MXPA01012936A (es) | Composicion farmaceutica que contiene sibutramina y orlistat. | |
DE10299023I1 (de) | Antineoplastisch wirkender und den Antineoplastischen effekt Verstaerkender Wirkstoff | |
HUP9903679A2 (hu) | Olanzapin alkalmazása bipoláris zavar kezelésére szolgáló gyógyszerkészítmények előállítására | |
ATE306278T1 (de) | Behandlung von knochenleiden mit adrenomedullin | |
LV11524A (lv) | Benzidamina izmantosana TNF izsaukto patologisko stavoklu arstesana | |
DK0541726T3 (da) | Vækstfaktorsammensætninger, fremstilling og anvendelse | |
TR200102262T2 (tr) | Koroner müdahale ile ilgili kardiovasküler olayların önlenmesi veya azaltılması için yöntem. | |
RU94002713A (ru) | Способ лечения детей с синдромом удлиненного интервала qт (романо-уорда) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |